Briacell Therap (NASDAQ:BCTX) Sees Significant Increase in Short Interest

Briacell Therap (NASDAQ:BCTX) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totaling 472,347 shares, a growth of 108.0% from the April 15th total of 227,052 shares. Currently, 6.6% of the company’s stock are sold short. Based on an average trading volume of 182,536 shares, the short-interest ratio is presently 2.6 days.

Wall Street Analysts Forecast Growth

BCTX has been the topic of several research reports. Wall Street Zen upgraded Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Briacell Therap presently has an average rating of “Sell”.

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new position in shares of Briacell Therap (NASDAQ:BCTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors.

Briacell Therap Stock Performance

NASDAQ BCTX traded down $1.03 during trading on Friday, hitting $3.02. The stock had a trading volume of 1,664,570 shares, compared to its average volume of 150,768. The company has a market capitalization of $21.90 million, a PE ratio of -0.13 and a beta of 1.26. The company’s 50-day moving average price is $4.14 and its two-hundred day moving average price is $6.28. Briacell Therap has a 12 month low of $2.98 and a 12 month high of $37.20.

Briacell Therap (NASDAQ:BCTX) last released its earnings results on Tuesday, March 10th. The company reported ($2.58) EPS for the quarter.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.